Sample Report — for illustration only. This is example data showing what your NextGen PGx PGx report looks like, not real results.
Personalized insights to help guide safer, more effective medication decisions.
Patient Name
John Smith
Date of Birth
01/15/1980
Report Date
September 9, 2026
Specimen Type
Buccal Swab
Report ID
GRX-1002345
Your DNA holds clues to how your body processes medications. This report highlights findings that may help you and your provider choose the safest, most effective options for you.
3
Important Genetic Consideration
These results may meaningfully affect how certain medications work for you. Share them with your healthcare provider.
8
Use With Additional Consideration
These results may influence medication choices or dosing. Your provider may take them into account when prescribing.
42
No Actionable PGx Finding Identified
For these medications, no genetic variations requiring a change in treatment were identified.
| Medication | Gene | Your Result | What This Means |
|---|---|---|---|
| Clopidogrel | CYP2C19 | Intermediate Metabolizer | May produce less active medication. Discuss alternative or monitoring with your healthcare provider. |
| Codeine | CYP2D6 | Poor Metabolizer | May have reduced pain relief. Discuss alternative options with your healthcare provider. |
| Simvastatin | SLCO1B1 | Decreased Function | May increase risk of muscle-related side effects. Discuss dose or alternative with your healthcare provider. |
| Medication | Gene | Your Result | Possible Significance |
|---|---|---|---|
| Citalopram | CYP2C19 | Intermediate Metabolizer | May affect medication exposure. |
| Escitalopram | CYP2C19 | Intermediate Metabolizer | May affect medication exposure. |
| Omeprazole | CYP2C19 | Intermediate Metabolizer | May affect drug concentrations. |
| Sertraline | CYP2C19 | Intermediate Metabolizer | May influence medication handling. |
| Celecoxib | CYP2C9 | Intermediate Metabolizer | May increase drug exposure. |
| Warfarin | CYP2C9/VKORC1 | Altered Sensitivity | Genetics may contribute to dose requirements. |
| Gene | Genotype | Predicted Phenotype | Impact Summary |
|---|---|---|---|
| CYP2D6 | *4/*4 | Poor Metabolizer | Reduced enzyme activity. May affect multiple medications. |
| CYP2C19 | *1/*2 | Intermediate Metabolizer | Reduced enzyme activity. May affect several medications. |
| CYP2C9 | *1/*3 | Intermediate Metabolizer | May affect medication processing and dose requirements. |
| SLCO1B1 | *1/*5 | Decreased Function | May increase risk of statin-related muscle side effects. |
Scan to view your full report online. Report ID: GRX-1002345
Show to your:
No Actionable PGx Finding Identified
For the remaining medications evaluated in this panel, no genetic variations requiring a change in treatment were identified. Always take medications as directed by your healthcare provider.